Key Players
Competitive Landscape
Four supplier models compete in the cholangiosarcoma market: global oncology groups, mutation-focused developers, regional commercialization partners and companion-diagnostic companies.
Since 2025 commercial investment has shifted toward regional biomarker launches and companion-diagnostic readiness. BeOne Medicines reported Chinese approval and launch of zanidatamab in August 2025 for HER2-positive biliary tract cancer. Roche received FDA approval in June 2025 to migrate the PATHWAY HER2 assay to the BenchMark ULTRA PLUS instrument. Oncology centers compare biomarker coverage, treatment-line evidence and administration needs ahead of manufacturer price negotiations.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Partner Therapeutics received FDA approval for Bizengri in May 2026 for previously treated NRG1 fusion-positive cholangiocarcinoma. | Specialists need a defined treatment option for an extremely rare fusion following prior systemic therapy failure. | Commercial competition is extending into smaller molecular subgroups that require regulator-defined testing and specialist administration routes. | Revenue is available through NRG1 testing and infusion-based treatment across experienced United States oncology centers. |
| BeOne Medicines reported Chinese approval and commercial launch of zanidatamab in August 2025 for previously treated HER2-high biliary tract cancer. | Chinese cancer centers need a licensed HER2 treatment route linked to a clear immunohistochemistry threshold for eligibility. | Regional rights holders are converting global biomarker assets into country-specific commercial pathways with local regulatory support. | Revenue is available through HER2 testing and targeted treatment across large Chinese hepatobiliary oncology networks. |
| The FDA approved Roche assay migration to the BenchMark ULTRA PLUS instrument in June 2025 for the PATHWAY HER2 test. | Pathology laboratories need standardized HER2 testing that operates on current automated staining platforms used across oncology services. | Companion diagnostics are becoming a required part of treatment access instead of a separate laboratory equipment purchase. | Revenue is available through assay installation and validated HER2 testing for Ziihera eligibility across equipped pathology laboratories. |
Incyte, Servier, Taiho, AstraZeneca, Merck and Molecular Partners compete through approved therapies or active programs without separate developments in this section.
Source: Future Market Insights, Cholangiosarcoma Market and Biliary Tract Cancers Treatment Market Reports, 2026-2036.
Partner Therapeutics and BeOne Medicines cover NRG1 and HER2 routes, while Roche supplies the PATHWAY assay for Ziihera eligibility.
Who leads the cholangiosarcoma market?
No company controls every cholangiosarcoma treatment route across first-line therapy and mutation-selected patient care pathways. AstraZeneca and Merck hold first-line checkpoint positions, while five specialists compete through authorized mutation-defined later-line indications.
Which suppliers have documented exact-market regulatory approvals?
Seven therapy companies hold regulator-backed indications for biliary tract or cholangiosarcoma populations across major treatment regions. Roche holds the authorized PATHWAY HER2 companion diagnostic indication used to confirm eligibility for Ziihera treatment.
Which companies provide biomarker-selected cholangiosarcoma therapies?
Incyte, Servier and Taiho supply FGFR2 or IDH1 medicines for mutation-defined populations receiving later treatment. Jazz Pharmaceuticals and Partner Therapeutics cover HER2-positive and NRG1 fusion-positive disease through regulator-authorized medicines for later-line patients.
Which suppliers serve North America and Europe?
Six companies maintain approved cholangiosarcoma or biliary tract cancer positions across North America and Europe. BeOne holds zanidatamab rights across Asia-Pacific, while Roche supports HER2 testing through international pathology laboratories.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| AstraZeneca PLC | Global | Imfinzi with gemcitabine and cisplatin for advanced biliary tract cancer. |
| Merck & Co., Inc. | Global | Keytruda with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer. |
| Incyte Corporation | Multi-region | Pemazyre for previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma. |
| Servier Pharmaceuticals LLC | Multi-region | Tibsovo for previously treated IDH1-mutated cholangiocarcinoma. |
| Taiho Pharmaceutical Co., Ltd. | Multi-region | Lytgobi for previously treated FGFR2 fusion or rearrangement-positive intrahepatic cholangiocarcinoma. |
| Jazz Pharmaceuticals plc | United States and Europe | Ziihera for previously treated HER2-positive biliary tract cancer. |
| Partner Therapeutics, Inc. | United States | Bizengri for previously treated NRG1 fusion-positive cholangiocarcinoma. |
| F. Hoffmann-La Roche Ltd. | Global diagnostics | PATHWAY anti-HER2 (4B5) assay for Ziihera eligibility. |
| Compass Therapeutics, Inc. | United States development base | Tovecimig with paclitaxel in a second-line biliary tract cancer program. |
| Molecular Partners AG | Switzerland and European study sites | MP0317 with standard chemoimmunotherapy in the Phase 2 TACTIC study. |
Research Methodology
The overview describes market structure without ranking companies and includes organizations through current exact-market evidence alone. Each company supplies a therapy, diagnostic, or development program for cholangiosarcoma or biliary tract cancer. Regulatory status belongs to approval holders, and FMI estimates targeted therapy at 39.0% during 2026.
